Canada's Valeant Pharmaceuticals International Inc. said its affiliate will sell its Dendreon cancer business to China's Sanpower Group Co. Ltd. for $819.9 million, as the drugmaker continues to shed its non-core assets to repay debt. …
SEATTLE--(BUSINESS WIRE)--Dendreon Corporation (Nasdaq:DNDN) today reported results for the third quarter ended September 30, 2013. Net product revenue for the quarter was $68 million compared to $77.9 million for the quarter …
NEW YORK (Reuters) – An experimental medicine from Dendreon Corp improved survival in men with advanced forms of prostate cancer, the company said on Tuesday, bolstering chances of it becoming the first approved therapeutic …
NEW YORK--(BUSINESS WIRE)-- Faruqi & Faruqi, LLP, a national law firm concentrating on investor rights, consumer rights and enforcement of federal antitrust laws, is investigating potential wrongdoing at Dendreon Corp. (“ Dendreon” or …
Beleaguered Valeant Pharmaceuticals International, Inc. VRX announced that its affiliate has entered into a definitive agreement to sell all the outstanding equity interests in Dendreon Pharmaceuticals, Inc. to the China based Sanpower …
SEATTLE--(BUSINESS WIRE)--Dendreon Corporation (Nasdaq: DNDN) today reported results for the fourth quarter and full year ended December 31, 2012. Net product revenue for the year ended December 31, 2012 was $325.3 million …